1. Kowall B, Rathmann W, Bongaerts B, et al. Incidence rates of type 2 diabetes in people with impaired fasting glucose (ADA vs. WHO Criteria) and impaired glucose tolerance: Results from an older population (KORA S4/F4/FF4 Study). Diabetes Care. 2019; 42(2): e18-e20. doi: 10.2337/dc18-1473
2. Kawasaki E, Nakamura K, Kuriya G, et al. Differences in the humoral autoreactivity to zinc transporter 8 between childhood- and adult-onset type 1 diabetes in Japanese patients. Clin Immunol. 2011; 138(2): 146-153. doi: 10.1016/j.clim.2010.10.007
3. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007; 104(43): 17040-17045. doi: 10.1073/pnas.0705894104
4. Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): A nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013; 62(2): 543-550 doi: 10.2337/db12-0207
5. Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care. 1993; 16(5): 780-788. doi: 10.2337/diacare.16.5.780
6. Buzzetti R, Di Pietro S, Giaccari A, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. 2007; 30(4): 932-938. doi: 10.2337/dc06-1696
7. Leslie RD, Palmer J, Schloot NC, et al. Diabetes at the crossroads: Relevance of disease classification to pathophysiology and treatment. Diabetologia. 2016; 59(1): 13-20. doi: 10.1007/s00125-015-3789-z
8. Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non–insulin-dependency: An open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017; 8(5):1123-1134. doi: 10.1007/s13300-017-0299-7
9. Aida K, Fukui T, Jimbo E, et al. Distinct Inflammatory Changes of the pancreas of slowly progressive insulin-dependent (Type 1) diabetes. Pancreas. 2018; 47(9): 1101-1109. doi: 10.1097/MPA.0000000000001144
10. Pieralice S, Pozzilli P. Latent autoimmune diabetes in adults: A review on clinical implications and management. Diabetes Metab J. 2018; 42(6): 451-464. doi: 10.4093%2Fdmj.2018.0190
11. Mishra R, Hodge KM, Cousminer DL, Leslie RD, Grant SFA. A global perspective of latent autoimmune diabetes in adults. Trends Endocrinol Metab. 2018; 29(9): 638-650. doi: 10.1016/j.tem.2018.07.001
12. Maddaloni E, Lessan N, Al Tikriti A, Buzzetti R, Pozzilli P, Barakat MT. Latent autoimmune diabetes in adults in the United Arab Emirates: Clinical features and factors related to insulin-requirement. PLoS One. 2015; 10(8): e0131837. doi: 10.1371/journal.pone.0131837
13. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2015; 38(1): S8-S16. doi: 10.2337/dc15-S005
14. Hernandez M, Mollo A, Marsal JR, et al. Insulin secretion in patients with latent autoimmune diabetes (LADA): Half way between type 1 and type 2 diabetes: Action LADA 9. BMC Endocr Disord. 2015; 15: 1. doi: 10.1186/1472-6823-15-1
15. Park Y, Wintergerst KA, Zhou Z. Clinical heterogeneity of type 1 diabetes (T1D) found in Asia. Diabetes Metab Res Rev. 2017; 33(7). doi: 10.1002/dmrr.2907
16. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: Current knowledge and implications for management. Nat Rev Endocrinol. 2017; 13(11): 674-686. doi: 10.1038/nrendo.2017.99
17. Takagi S, Miura J, Hoshina S, Uchigata Y, Babzono T. Association of anti-GAD antibody positivity measured by RIA and ELISA with clinical characteristics in patients with type 1 diabetes. Diabetes. 2018; 67(1). doi: 10.2337/db18-1700-P
18. Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care. 2013; 36(4): 908-913. doi: 10.2337/dc12-0931
19. Buzzetti R, Spoletini M, Zampetti S, et al. Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. Diabetes Care. 2015; 38(3): 513-520. doi: 10.2337/dc14-1638
20. Rawshani A, Landin-Olsson M, Svensson AM, et al. The incidence of diabetes among 0-34 year olds in Sweden: New data and better methods. Diabetologia. 2014; 57(7): 1375-1381. doi: 10.1007/s00125-014-3225-9
21. Sachan A, Zaidi G, Sahu RP, Agrawal S, Colman PG, Bhatia E. Low prevalence of latent autoimmune diabetes in adults in northern India. Diabet Med. 2015; 32(6): 810-813. doi: 10.1111/dme.12644